Genomic Expression (GE) has the potential to save lives and drastically improve health outcomes for those with diseases and cancer. GE’s OneRNA technology analyzes a patient’s RNA in their tumor sample and identifies FDA approved treatment options or clinical studies for patients not responding to standard treatments. This analysis have already saved patients lives in numerous cancer types, and the technology is now clinically validated and ready to launch in breast and ovarian cancer. The OneRNA Platform enables truly individualized vaccines, the repurposing of existing drugs, and speeds up the manufacturing process of individualized vaccines from nine weeks to one. OneRNA enables the control of genes by turning them up or down, while most drug modalities can only turn genes down. In summary, OneRNA® is saving lives today and can accelerate and de-risk future drug discovery and development by rapidly translating RNA data to new RNA drugs and novel combinatorial treatment solutions.
